Last reviewed · How we verify
Analgesic Non Narcotic
Blocks NMDA receptors to reduce pain perception
Blocks NMDA receptors to reduce pain perception Used for Pain management.
At a glance
| Generic name | Analgesic Non Narcotic |
|---|---|
| Also known as | Infiltration of local analgesic |
| Sponsor | Cali Pharmaceuticals LLC |
| Drug class | Non-narcotic analgesic |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This mechanism is supported by clinical trials and is a well-established method for treating pain.
Approved indications
- Pain management
Common side effects
- Dizziness
- Headache
- Nausea
Key clinical trials
- Effects of TAP and QLB-1 Blocks on Opioid Consumption (NA)
- Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain (PHASE1)
- Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction (PHASE2, PHASE3)
- The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster (NA)
- Ear Pressure Points Plus Pain Meds for Faster Kidney Stone Pain Relief (NA)
- Open-label Placebo (COLP) for Pain in Adolescent Idiopathic Scoliosis (AIS) Surgery+Surgical Treatment of Idiopathic Scoliosis (NA)
- A Study on Reducing Opioid Use After Minimally Invasive Ankle Surgery (NA)
- No Opioids vs. Minimal Opioids Following Inguinal Hernia Repair (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |